The concurrent chemoradiation paradigm—general principles
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,General Medicine
Link
http://www.nature.com/articles/ncponc0714.pdf
Reference132 articles.
1. Steel GG and Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85–91
2. Brizel DM et al. (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18: 3339–3345
3. Buentzel J et al. (2006) Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64: 684–691
4. Komaki R et al. (2004) Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58: 1369–1377
5. Malik R et al. (2005) Meta-analysis of the effect of amifostine on response rates in advanced non-small cell lung cancer patients treated on randomized trials. Int J Radiat Oncol Biol Phys 63 (Suppl 1): S117
Cited by 342 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Combining radiation and systemic therapy;Palliative Radiation Oncology;2024
2. Stability-Enhanced Cisplatin Gold Nanoparticles as Therapeutic Anticancer Agents;ACS Applied Nano Materials;2023-12-22
3. To radiate or not to radiate: that is the question?—a commentary on “Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial”;Chinese Clinical Oncology;2023-12
4. Journey of Natural Products: From Isolation Stage to Drug’s Approval in Clinical Trials;Bioactivities;2023-09-12
5. Impact of fractionated cisplatin and radiation treatment on cell growth and accumulation of DNA damage in two normal cell types differing in origin;Scientific Reports;2023-09-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3